Genmab — Januar 2019

[StockBull]

Johnson & Johnson beats by $0.02, beats on revenue

[E_L]

So we get to 2025 total 2018

[E_L]

that is roughly where i thought it would be, but probably a bit light compared to consensus

[E_L]

https://www.prnewswire.com/news-releases/johnson--johnson-reports-2018-fourth-quarter-results-300781914.html

[bibob]

Og på kursen.

[Legolas23]

Det er vel indtil nu. Regnskabsåret for genmab er jo ikke slut endnu.

[bibob]

Nej, men ser ud til Dara salget ikke går så godt endda

[StockBull]

er der nogen guidance for 2019 m.h.t dara

[StockBull]

The Company announced its 2019 full-year guidance for sales of $80.4 billion to $81.2 billion reflecting expected operational growth in the range of 0.0% to 1.0% and expected adjusted operational growth in the range of 2.0% to 3.0%. The Company also announced adjusted earnings guidance for full-year 2019 of $8.50 to $8.65 per share reflecting expected operational growth in the range of 5.7% to 7.6%.* Adjusted earnings guidance excludes the impact of after-tax intangible amortization expense and

[StockBull]

Salget er steget 16% fra Q3 til Q4 så det er sku da ikke helt dårligt

[StockBull]

1Q18 432
2Q18 505
3Q18 504
4Q18 584

[Bulder]

Helt dårligt er det ikke. Row ok. Us dårligt.

[Bulder]

Med rabatterne indregnet steg row 45% fra q3 til q4.

[StockBull]

Ser for mig ud til at 2019 kan blive ca. 2.5 uden MAIA

[kkjoel]

Nej SB, tallene for 19 er: Q1 432 Q2 511 Q3 498 Q4 584.

[E_L]

on 12.54 as expected i think, ROW starts benefitting from 1st line, hopefully we'll see the same in US soon

[bibob]

Vi mangler salg i første linie i US. Hvis og når det kommer må kurven blive knækket. Det ville nok også hjælpe gevaldigt med Dara sc.

[kkjoel]

Og ja, 3 mia. ser svært ud UDEN
MAIA for 19H2.

[StockBull]

1Q19 613.2
2Q19 643.86
3Q19 826.053
4Q19 1067.35565

[StockBull]

Jeg ser 3.15 med MAIA i hele H2-2019